Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Qiming readies to deploy $1.1B new China fund in the age of COVID-19

With largest fund yet, the firm will invest in biopharma, devices, diagnostics, services and healthcare IT

Now that it has closed its new $1.1 billion fund, Qiming will begin plotting its path through the economic downturn caused by COVID-19 by capitalizing on low valuations and fewer competing investors for assets.

Managing Partner Nisa Leung, who has led Qiming’s healthcare investments since 2006, told BioCentury the new fund is the biggest yet for the firm, which has more than $5 billion under management.

Nearly all of the largest LPs from

Read the full 726 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers